USV Introduces Heart Failure Medication “OnArni’’

This introduction aims to provide an affordable solution for the management of heart failure in India, a country witnessing a significant rise in such cases.

Mumbai-based pharmaceutical firm USV has launched its latest heart failure treatment, OnArni. It combines Sacubitril and valsartan and is priced at INR 8 per 50 mg tablet. 

This introduction aims to provide an affordable solution for the management of heart failure in India, a country witnessing a significant rise in such cases.

Growing Concern of Heart Failure

India is grappling with an alarming increase in heart failure cases, with patients developing the condition nearly a decade earlier than in other parts of the world. This trend puts immense pressure on families and the already strained healthcare system. 

Heart failure, often a lifelong condition, demands regular medication, which can lead to frequent hospitalization and increased medical expenses. 

The high cost of treatment makes it difficult for many patients to maintain consistency in their medication, ultimately worsening their health outcomes. The introduction of OnArni by USV addresses this issue by offering a bioequivalent and cost-effective alternative to existing treatments.

Financial Burden of Heart Failure

Managing heart failure involves expensive, long-term medication and care, which places a heavy financial burden on patients. 

USV's OnArni provides an affordable treatment option aimed at alleviating this burden. By pricing the tablet at INR 8 for the starting dose, USV ensures that patients can access the medication they need without compromising quality.

Prashant Tewari, MD of USV, highlighted the company's commitment to affordable cardiovascular care. 

He stated, "As leaders in cardiovascular care, introducing bioequivalent OnArni was a pivotal step for us at USV to ensure heart failure treatment is both affordable and accessible. With a price of INR 8 per tablet of the starting dose, OnArni helps patients stay consistent with their medication, which is critical in managing the condition effectively. By alleviating the financial strain that often leads patients to skip doses, we aim to reduce hospital readmissions and improve long-term health outcomes.”

This move by USV is expected to help patients better adhere to their treatment plans, preventing complications that often arise from inconsistent medication use. By making heart failure treatment more accessible, USV aims to improve long-term health outcomes and reduce hospital readmissions due to poor medication adherence.

USV’s introduction of OnArni is timely, as heart failure continues to affect millions across the country. Sacubitril and Valsartan, offered in OnArni, are widely regarded as effective treatments for heart failure. USV's version provides a bioequivalent alternative that ensures affordability without compromising treatment efficacy.

The company’s decision to launch OnArni at such a low price point is expected to ease the financial strain many families experience due to heart failure management. Given the rising number of heart failure cases in India, particularly among younger populations, this development marks an important step toward improving access to life-saving medications.

USV’s OnArni offers a practical and immediate solution for heart failure patients, delivering a cost-effective option in a healthcare landscape where affordability often dictates patients' quality of care. Stay tuned for more such updates on Digital Health News.